Erbb3 and Hspa2, two novel predictors of heart failure in diabetic patients

Maurizio Forte¹, Mattia Galli^{2

3}, Sebastiano Sciarretta^{1

3}

Affiliations

¹ Department of Angiocardioneurology, IRCCS Neuromed, via Atinense 18, Pozzilli 86077, Italy.
² GVM Care & Research, Maria Cecilia Hospital, Cotignola, Italy.
³ Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, Latina 04100, Italy.

Editorial

Maurizio Forte et al. Cardiovasc Res. 2024.

. 2024 Dec 4;120(15):1827-1829.

doi: 10.1093/cvr/cvae220.

Maurizio Forte¹, Mattia Galli^{2

3}, Sebastiano Sciarretta^{1

3}

¹ Department of Angiocardioneurology, IRCCS Neuromed, via Atinense 18, Pozzilli 86077, Italy.
² GVM Care & Research, Maria Cecilia Hospital, Cotignola, Italy.
³ Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, Latina 04100, Italy.

No abstract available

Conflict of interest statement

Conflict of interest: none declared.

The diabetic myocardial transcriptome reveals Erbb3 and Hspa2 as a novel biomarkers of incident heart failure.
Conning-Rowland MS, Giannoudi M, Drozd M, Brown OI, Yuldasheva NY, Cheng CW, Meakin PJ, Straw S, Gierula J, Ajjan RA, Kearney MT, Levelt E, Roberts LD, Griffin KJ, Cubbon RM. Conning-Rowland MS, et al. Cardiovasc Res. 2024 Dec 4;120(15):1898-1906. doi: 10.1093/cvr/cvae181. Cardiovasc Res. 2024. PMID: 39180332 Free PMC article.